CH527207A
(en)
|
1968-05-08 |
1972-08-31 |
Ceskoslovenska Akademie Ved |
Process for the preparation of 1-glycosyl-5-azacytosines
|
DE2105468A1
(en)
|
1970-04-23 |
1971-11-18 |
Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen |
1-glycosyl-5-aza-cytosines prepn
|
US5157120A
(en)
|
1980-09-16 |
1992-10-20 |
Syntex (U.S.A.) Inc. |
Guanine derivatives
|
US4534899A
(en)
|
1981-07-20 |
1985-08-13 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
US4855304A
(en)
|
1985-01-10 |
1989-08-08 |
Repligen Corporation |
Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
|
JPS61176523A
(en)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
Carcinostatic agent
|
GB8612826D0
(en)
|
1986-05-27 |
1986-07-02 |
Boots Co Plc |
Insecticidal compositions
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US4920016A
(en)
|
1986-12-24 |
1990-04-24 |
Linear Technology, Inc. |
Liposomes with enhanced circulation time
|
DE3712786A1
(en)
|
1987-04-15 |
1988-11-03 |
Merck Patent Gmbh |
METHOD AND MEANS FOR DETERMINING NUCLEIC ACIDS
|
CS269077B1
(en)
|
1987-10-01 |
1990-04-11 |
Piskala Alois |
Method of 5-azacytosines preparation
|
US5736531A
(en)
|
1987-10-28 |
1998-04-07 |
Pro-Neuron, Inc. |
Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
|
US5968914A
(en)
|
1987-10-28 |
1999-10-19 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
US4904770A
(en)
|
1988-03-24 |
1990-02-27 |
Bristol-Myers Company |
Production of 2',3'-dideoxy-2',3'-didehydronucleosides
|
US5324831A
(en)
|
1988-04-06 |
1994-06-28 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Phosphoramidite reagent for chemical synthesis of modified DNA
|
GB8824593D0
(en)
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
PT93772A
(en)
|
1989-04-17 |
1991-01-08 |
Searle & Co |
PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF NEOPLASMS, CONTAINING AN ANTI-NEOPLASTIC AGENT, FOR EXAMPLE DOXORUBICIN AND A PROTEIN AGENT TO REDUCE THE SIDE EFFECTS, FOR EXAMPLE CARBETIMER
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5665710A
(en)
|
1990-04-30 |
1997-09-09 |
Georgetown University |
Method of making liposomal oligodeoxynucleotide compositions
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
ZA923640B
(en)
|
1991-05-21 |
1993-02-24 |
Iaf Biochem Int |
Processes for the diastereoselective synthesis of nucleosides
|
JP3220180B2
(en)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
Drug-containing protein-bound liposomes
|
CA2504078C
(en)
|
1991-07-05 |
2007-08-28 |
Wellstat Therapeutics Corporation |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
IL103311A0
(en)
|
1991-10-07 |
1993-03-15 |
Univ Johns Hopkins |
Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
|
JPH05219974A
(en)
|
1992-02-13 |
1993-08-31 |
Mitsui Petrochem Ind Ltd |
Production of tropane alkaloid
|
JPH05246891A
(en)
|
1992-03-09 |
1993-09-24 |
Kobayashi Seiyaku Kogyo Kk |
Stable antipancreatitic parenteral solution
|
FR2692265B1
(en)
|
1992-05-25 |
1996-11-08 |
Centre Nat Rech Scient |
BIOLOGICALLY ACTIVE COMPOUNDS OF THE PHOSPHOTRIESTER TYPE.
|
US5607691A
(en)
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
JP3351476B2
(en)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
Phospholipid derivatives and liposomes containing the same
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
FR2705099B1
(en)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Phosphorothioate triester oligonucleotides and process for their preparation.
|
AU6081294A
(en)
|
1993-05-14 |
1994-12-12 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
GB9311252D0
(en)
|
1993-06-01 |
1993-07-21 |
Hafslund Nycomed As |
Cell growth regualtors
|
US6184211B1
(en)
|
1993-11-30 |
2001-02-06 |
Methylgene Inc. |
Inhibition of DNA methyltransferase
|
CA2137297C
(en)
|
1993-12-06 |
2000-04-18 |
Tsuyoshi Miyazaki |
Reactive vesicle and functional substance-fixed vesicle
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
US5856090A
(en)
|
1994-09-09 |
1999-01-05 |
The Scripps Research Institute |
DNA-methylase linking reaction
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
US20030104576A1
(en)
|
1994-10-07 |
2003-06-05 |
Jonathan W. Nyce |
Dna construct, composition, formulations & methods for making the construct & for modulating expression
|
EP0871707A4
(en)
|
1995-05-19 |
2000-10-25 |
Phytera Inc |
Manipulation of plant cell and tissue cultures
|
AU706026B2
(en)
|
1995-06-06 |
1999-06-10 |
Case Western Reserve University |
Myogenic differentiation of human mesenchymal stem cells
|
US5756122A
(en)
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
DE69629702T2
(en)
|
1995-08-01 |
2004-06-17 |
Isis Pharmaceuticals, Inc., Carlsbad |
LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS
|
US5858397A
(en)
|
1995-10-11 |
1999-01-12 |
University Of British Columbia |
Liposomal formulations of mitoxantrone
|
RU98113785A
(en)
|
1995-12-22 |
2000-06-10 |
Ист Каролина Юниверсити (US) |
AGENT AND METHOD FOR TREATING DISEASES ASSOCIATED WITH AN EXCESSIVE EXPRESSION OF CYTIDINDESYNAMINASES OR DESOXICYTIDINESINASES
|
PT1132393E
(en)
|
1996-10-16 |
2003-08-29 |
Ribapharm Inc |
L-RIBAVIRIN AND USES OF THE SAME
|
US6423692B2
(en)
|
1997-04-24 |
2002-07-23 |
Dana-Farber Cancer Institute, Inc. |
Method of enhancing the effectiveness of DCK phosphorylated molecules
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
JP4768121B2
(en)
|
1998-02-05 |
2011-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Tumor associated antigens from the MAGE family and the nucleic acid sequences encoding them, the use of fusion proteins and for the preparation of compositions for vaccination
|
ATE275956T1
(en)
|
1998-10-19 |
2004-10-15 |
Methylgene Inc |
ALTERATION OF DNA METHYLTRANSFERASE THROUGH COMBINATION THERAPY
|
KR100856446B1
(en)
|
1998-12-23 |
2008-09-04 |
화이자 인크. |
Human monoclonal antibodies to ctla-4
|
AU3469400A
(en)
|
1999-01-05 |
2000-07-24 |
Clarence C. Lee |
Pharmaceutical compositions for treatment of diseased tissues
|
AU4347500A
(en)
|
1999-04-13 |
2000-11-14 |
Rutgers, The State University Of New Jersey |
Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
|
IL146872A0
(en)
|
1999-06-03 |
2002-08-14 |
|
Methods and compositions for modulating cell proliferation and cell death
|
DE19935303A1
(en)
|
1999-07-28 |
2001-02-08 |
Aventis Pharma Gmbh |
Oligonucleotides to inhibit the expression of human eg5
|
EP2829609A1
(en)
|
1999-08-24 |
2015-01-28 |
E. R. Squibb & Sons, L.L.C. |
Human CTLA-4 antibodies and their uses
|
JP2001163776A
(en)
|
1999-09-30 |
2001-06-19 |
Nisshin Oil Mills Ltd:The |
Stabilized liquid agent
|
AU785115B2
(en)
|
1999-10-18 |
2006-09-21 |
Emory University |
TMS1 compositions and methods of use
|
AU2001247444A1
(en)
|
2000-03-15 |
2001-09-24 |
University Of Massachusetts |
Erbeta-mediated gene expression
|
EP1315970B1
(en)
|
2000-09-08 |
2010-03-17 |
Seoul National University Industry Foundation |
Nucleic acid sequence and protein involved in cellular senescence
|
US6858935B1
(en)
|
2000-12-07 |
2005-02-22 |
Cadence Design Systems, Inc. |
Simulating euclidean wiring directions using manhattan and diagonal directional wires
|
EP1351678A2
(en)
|
2001-01-02 |
2003-10-15 |
Elizabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
RS50236B
(en)
|
2001-01-22 |
2009-07-15 |
Merck & Co.Inc., |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
JP2002223753A
(en)
|
2001-01-30 |
2002-08-13 |
Hitachi Ltd |
Oligonucleotide array for analyzing drug response
|
ES2252461T3
(en)
|
2001-02-05 |
2006-05-16 |
Innoventus Project Ab |
GLICOPROTEIN RICH IN HISTIDINE (HRGP) FOR THE INHIBITION OF ANGIOGENESIS.
|
US6613753B2
(en)
|
2001-02-21 |
2003-09-02 |
Supergen, Inc. |
Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
|
AU2002252183A1
(en)
|
2001-03-06 |
2002-09-19 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
US20060194275A1
(en)
|
2001-04-13 |
2006-08-31 |
Incyte Corporation |
Transporter and ion channels
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
EP2283845A1
(en)
|
2001-04-26 |
2011-02-16 |
pSivida Inc. |
Sustained release drug delivery system containing codrugs
|
US20030148973A1
(en)
|
2001-05-23 |
2003-08-07 |
Peter Emtage |
MAGE-A1 peptides for treating or preventing cancer
|
WO2002101353A2
(en)
|
2001-06-08 |
2002-12-19 |
U.S. Genomics, Inc. |
Methods and products for analyzing nucleic acids based on methylation status
|
JP2002370939A
(en)
|
2001-06-12 |
2002-12-24 |
Taisho Pharmaceut Co Ltd |
Hair growth tonic
|
SE0102627L
(en)
|
2001-07-27 |
2002-11-19 |
Geneinvent Bbl Ab |
Vectors resistant to methylation
|
US20030045497A1
(en)
|
2001-07-27 |
2003-03-06 |
Geneinvent Bbl Ab |
Methylation resistant vectors
|
WO2003012085A1
(en)
|
2001-07-30 |
2003-02-13 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antigen presenting cells, method for their preparation and their use for cancer vaccines
|
ATE548041T1
(en)
|
2001-09-05 |
2012-03-15 |
Chemgenex Pharmaceuticals Ltd |
HOMOHARRINGTONINS ALONE OR IN COMBINATION WITH OTHER SUBSTANCES FOR USE IN THE TREATMENT OF CHRONIC MYELOGENEIC LEUKEMIA RESISTANT OR INTOLERANT TO PROTEIN KINASE INHIBITORS EXCEPT STI 571
|
IN2014DN10834A
(en)
|
2001-09-17 |
2015-09-04 |
Psivida Inc |
|
US20030158598A1
(en)
|
2001-09-17 |
2003-08-21 |
Control Delivery Systems, Inc. |
System for sustained-release delivery of anti-inflammatory agents from a coated medical device
|
WO2003026574A2
(en)
|
2001-09-24 |
2003-04-03 |
Au Jessie L-S |
Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
|
AU2002342004A1
(en)
|
2001-10-05 |
2003-04-22 |
Case Western Reserve University |
Methods and compositions for detecting colon cancers
|
EP1452592A4
(en)
|
2001-11-08 |
2006-02-15 |
Japan Science & Tech Agency |
Rice transposon genes
|
EP1492523A2
(en)
|
2001-11-23 |
2005-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method for identification of tumor targeting enzymes
|
IL161832A0
(en)
|
2001-11-29 |
2005-11-20 |
Dandrit Biotech As |
Pharmaceutical composition for inducing an immune response in a human or animal
|
US20050080027A1
(en)
|
2001-11-30 |
2005-04-14 |
Markus Horer |
Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
|
GB0201498D0
(en)
|
2002-01-23 |
2002-03-13 |
Biotech Res Ventures Pte Ltd |
Materials and methods for treating cancer
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
CA2478640A1
(en)
|
2002-03-13 |
2003-09-18 |
F. Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
JP2003310293A
(en)
|
2002-04-26 |
2003-11-05 |
Mitsui Chemicals Inc |
Method for producing nucleoside compound
|
HUE030806T2
(en)
|
2002-05-02 |
2017-05-29 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
WO2003104427A2
(en)
|
2002-06-05 |
2003-12-18 |
Case Western Reserve University |
Methods and compositions for detecting cancers
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
WO2004041195A2
(en)
|
2002-10-31 |
2004-05-21 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
US20050037992A1
(en)
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
WO2005033278A2
(en)
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
ATE422367T1
(en)
|
2004-05-26 |
2009-02-15 |
Biovaxim Ltd |
COMPOSITIONS OF DEMETHYLATING AGENTS AS IMMUNOTHERAPY ENHANCERS FOR THE TREATMENT OF CHRONIC INFECTIONS AND NEOPLASTIC DISEASES AND TREATMENT METHODS THEREOF
|
US20060014949A1
(en)
|
2004-07-13 |
2006-01-19 |
Supergen Inc. |
Compositions and formulations of decitabine polymorphs and methods of use thereof
|
US20060069060A1
(en)
|
2004-09-27 |
2006-03-30 |
Sanjeev Redkar |
Salts of decitabine
|
US20060063735A1
(en)
|
2004-09-17 |
2006-03-23 |
Supergen, Inc. |
Salts of 5-azacytidine
|
MX2007003804A
(en)
|
2004-11-04 |
2007-04-23 |
Pfizer Prod Inc |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer.
|
US20060128653A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
AU2005321898B2
(en)
|
2004-12-29 |
2012-07-19 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
US7250416B2
(en)
|
2005-03-11 |
2007-07-31 |
Supergen, Inc. |
Azacytosine analogs and derivatives
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Substituted Amid derivatives & methods of use
|
LT2439273T
(en)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
CN105330741B
(en)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US20070105792A1
(en)
|
2005-11-04 |
2007-05-10 |
Dimartino Jorge F |
Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
|
US20070117776A1
(en)
|
2005-11-04 |
2007-05-24 |
John Lyons |
Low Dose Therapy Of DNA Methylation Inhibitors
|
CN101361718B
(en)
|
2008-09-26 |
2013-08-28 |
深圳万乐药业有限公司 |
Stable preparation method of decitabine freeze-dry preparation
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
WO2012033953A1
(en)
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
WO2012140627A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
AU2012302051B2
(en)
|
2011-08-30 |
2017-04-27 |
Astex Pharmaceuticals, Inc. |
Decitabine derivative formulations
|
US9872873B2
(en)
|
2012-02-06 |
2018-01-23 |
Fresenius Kabi Oncology Limited |
Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
|
SG10201707135RA
(en)
|
2013-03-01 |
2017-10-30 |
Astex Pharmaceuticals Inc |
Drug combinations
|
EP3316685A4
(en)
|
2015-07-02 |
2019-03-13 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
US20210147466A1
(en)
|
2017-07-11 |
2021-05-20 |
Teva Czech Industries S.R.O. |
Improved processes for the preparation of guadecitabine and intermediates thereof
|
WO2019025863A2
(en)
|
2017-08-03 |
2019-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|